Adaptive Biotechnologies upgraded by Goldman with a new price target
$ADPT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Goldman upgraded Adaptive Biotechnologies from Neutral to Buy and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $15.00 | Buy | Craig Hallum |
| 3/21/2025 | $9.00 | Neutral → Buy | Goldman |
| 7/5/2023 | $15.00 | Overweight | JP Morgan |
| 1/5/2023 | $15.00 | Sector Outperform | Scotiabank |
| 12/21/2022 | $7.50 → $14.00 | Neutral → Overweight | Piper Sandler |
| 8/25/2022 | $8.00 | Underperform | Credit Suisse |
| 6/3/2022 | $7.50 | Neutral | Piper Sandler |
| 2/16/2022 | $40.00 → $32.00 | Buy | BofA Securities |